Screen LibrarySymposium on Clinical Pharmacology : [papers] : held at the Hotel Robert Mayer, Jacksonville, Florida, March 12-13, 1973 /
Symposium on Clinical Pharmacology reviews advances in clinical pharmacology, with emphasis on how to materially improve the efficacy of cancer chemotherapy. Topics range from absorption, protein binding, distribution, and excretion of antineoplastic drugs to factors affecting the biotransformation...
Saved in:
| Corporate Authors: | ; ; |
|---|---|
| Group Author: | ; ; |
| Published: |
Pergamon Press,
|
| Publisher Address: | New York : |
| Publication Dates: | 1975. |
| Literature type: | eBook |
| Language: | English |
| Series: |
Biochemical pharmacology : Supplement ;
v. 23, 1974, no. 2 |
| Subjects: | |
| Online Access: |
http://www.sciencedirect.com/science/book/9780080189499 |
| Summary: |
Symposium on Clinical Pharmacology reviews advances in clinical pharmacology, with emphasis on how to materially improve the efficacy of cancer chemotherapy. Topics range from absorption, protein binding, distribution, and excretion of antineoplastic drugs to factors affecting the biotransformation and activity of antitumor drugs. The transport of tumor-inhibitory agents across cell membranes is also examined, together with factors influencing drug selectivity and the mechanisms of clinical drug resistance. This volume is comprised of 23 chapters and begins with a brief summary of the differen. |
| Carrier Form: | 1 online resource (iv, 236 pages) : illustrations. |
| Bibliography: | Includes bibliographical references. |
| ISBN: |
9781483139401 1483139409 |
| Index Number: | RC271 |
| CLC: | R730.53 |
| Contents: |
Front Cover; Symposium on Clinical Pharmacology; Copyright Page; Table of Contents; INTRODUCTORY REMARKS; PART 1: PHARMACOLOGICAL FACTORS IN DRUG ACTION; PART 2: FACTORS INFLUENCING DRUG SELECTIVITY; PART 3: MECHANISMS OF CLINICAL DRUG RESISTANCE; PART 4: COMBINATION CHEMOTHERAPY; PART 5: NEW INFORMATION ON MECHANISMS OF DRUG ACTION; CHAPTER 1. PHARMACOKINETICS AND DRUG EFFECT; Classical pharmacokinetic models; Physiological pharmacokinetic model; Methotrexate kinetics and effect; REFERENCES; CHAPTER 2. ABSORPTION, PROTEIN BINDING, DISTRIBUTION AND EXCRETION OF ANTINEOPLASTIC DRUGS. Operational cytokinetics of bone marrow and intestineDescriptive cytokinetics of tumors; Operational cytokinetics of tumors; Comparison between the descriptive and operational approaches to cytokinetics; C O N C L U S I O N S; REFERENCES; CHAPTER 8. ROLE OF ENZYMATIC ACTIVATION AND INACTIVATION IN DRUG SELECTIVITY; Purine and pyrimidine antimetabolites; Cyclophosphamide and dimethyl-triazeno-imidazole carboxamide; Other drugs inactivated in insensitive tissues; Inactivation followed by reactivation; CONCLUSIONS; REFERENCES. CHAPTER 9. GENERAL MECHANISMS OF CLINICAL RESISTANCE TO CANCER CHEMOTHERAPYREFERENCES; CHAPTER 10. MECHANISMS OF CLINICAL DRUG RESISTANCE TO ALKYLATING AGENTS; CLASSES OF ALKYLATING AGENT AND MECHANISM OF ACTION; DEFINITION OF RESISTANCE; CONCLUSIONS; REFERENCES; CHAPTER 11. RESISTANCE TO FOLIC ACID ANTAGONISTS -CLINICAL ASPECTS; General considerations; Resistance to MTX in experimental tumors; Resistance to MTX in man; Prevention and exploitation of folate antagonist resistance; REFERENCES; CHAPTER 12. RESISTANCE TO PURINE ANALOGS; CONCLUSIONS; REFERENCES. CHAPTER 13. CLINICAL RESISTANCE TO ANTIPYRIMIDINE ANTICANCER DRUGSFluorouracil; Clinical pharmacologic attacks on pyrimidine-resistant tumors; REFERENCES; CHAPTER 14. BIOCHEMICAL AND PHARMACOLOGICAL PRINCIPLES OF COMBINATION CHEMOTHERAPY; REFERENCES; CHAPTER 15. THERAPEUTIC SYNERGISM IN ANIMAL MODELS -- INCREASED ANTITUMOR SPECIFICITY RESULTING FROM DIMINISHED TOXICITY FOR THE HOST; REFERENCES; CHAPTER 16. SCHEDULE-DEPENDENT SYNERGISM AND ANTAGONISM BETWEEN METHOTREXATE AND ASPARAGINASE; METHODS AND MATERIALS; RESULTS; DISCUSSION; REFERENCES. |